Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation

Molecular Carcinogenesis

Volumn 29, Issue 4, 2000, Pages 236-250

  Jiang, Cheng ^a   Ganther, Howard ^b   Lu, Junxuan ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Angiogenesis; Matrix metalloproteinase 2; Methylselenol; Mitogen activated protein kinase; Selenium; Vascular endothelial growth factor

Indexed keywords

GELATINASE A; METHYLSELENINIC ACID; METHYLSELENOCYANATE; SELENIDE; SELENIUM; SELENIUM DERIVATIVE; SODIUM SELENITE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CELL GROWTH; CELL LYSATE; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UMBILICAL VEIN; ZYMOGRAPHY;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; HUMANS; LYMPHOKINES; MATRIX METALLOPROTEINASE 2; METHANOL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOSELENIUM COMPOUNDS; SELENIUM; TIME FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

BOVINAE;

EID: 0034518874     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2744(200012)29:4<236::AID-MC1006>3.0.CO;2-E     Document Type: Article

References (54)

1. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial
2. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong
3. The Linxian trials: Mortality rates by vitamin-mineral intervention group
4. Lessons from basic research in selenium and cancer prevention
5. Chemopreventive agents: Selenium
6. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake
7. Tumor angiogenesis: Therapeutic implications
8. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
9. How tumors become angiogenic
10. Angiogenesis and tumor metastasis
11. Activity of methylated forms of selenium in cancer prevention
12. Chemical form of selenium, critical metabolites, and cancer prevention
13. Matrix metalloproteinases and the development of cancer
14. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
15. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2
16. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
17. Vascular endothelial growth factor is a secreted angiogenic mitogen
18. Vascular permeability factor, an endothelial cell mitogen related to PDGF
19. Vascular permeability factor/vascular endothelial growth factor and vascular stroma formation in neoplasia. Insights from in situ hybridization studies
20. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma
21. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
22. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
23. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
24. Tumor induction of VEGF promoter activity in stromal cells
25. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer
26. The mitogen-activated protein kinase signal transduction pathway
27. MAPKs: New JNK expands the group
28. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells
29. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase
30. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
31. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases
32. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor
33. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
34. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway
35. Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention
36. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures
37. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill
38. Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells
39. Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage
40. Dissociation of the genotoxic and growth inhibitory effects of selenium
41. Effect of an aqueous extract of selenium enriched garlic on in vitro markers and in vivo efficacy in cancer prevention
42. Differential induction of growth arrest inducible genes by selenium compounds
43. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells
44. Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells
45. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
46. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
47. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
48. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor
49. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
50. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
51. VEGF deprivation-induced apoptosis is a component of programmed capillary regression
52. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
53. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
54. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF